Professional Documents
Culture Documents
promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine
Association-Limited.'in,October-1949. The present management took over in November 1975 when the total turnover of the
companywasjust-Rs.0.54crores. Currently, this premise where Ipca started its operations, houses the Registered Office of the
company. Key departments like International Marketing, R&D (Formulations) and Analytical Development Lab are located here.
Prorfile: Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca's
APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including
the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-
Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods
Administration (TGA). With operations in over 100 countries, exports account for over 52% of the company's income. Forbes, a
leading US business magazine, selected Ipca in 2003 among its top 200 successful, rising companies outside USA, with sales under
USD 1 Billion. Over 19,000 companies were considered by Forbes, and of the 18 companies from India that figured in this list, only
four were from the 'Indian Pharmaceutical Sector'. Ipca happens to be one of them. Subsequently, Ipca was selected by FORBES in
this prestigious list for two consecutive years; 2004 and 2005.
From a modest income of Rs. 0.54 crores in 1975-76, the net income has soared to Rs. 753.30 crores in 2005-06 with exports
accounting for Rs. 401.83 crores. The net profit for the year ending 31st March, 2006 stood at Rs. 63.98 crores. Formulations
constitute 67 percent of the total income for 2005-06. Today, Ipca is one of the biggest manufacturers in the world of APIs Atenolol
(Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic
stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over.
BOARD OF DIRECTOR--------- Mr. M. R. Chandurkar, Mr. Babulal Jain, Dr. V. V. Subba Rao, Mr. V. A.
Gore
Last year achievements:
2007
January - Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Atenolol Tablets
March - Ipca launched eighth domestic marketing division, 'Altus' which caters to intensivists and surgeons.
March - Ipca's New Biotech Research & Development Unit was inaugurated at Mumbai.
June - Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Hydroxy Chloroquine Sulfate Tablets
July - Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Hydrochlorothiazide (HCTZ) Tablets.
August - Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Metformin HCl Tablets.
September - Acquisition of 100% shareholding of Formulation Dossier registration holding companies in Austr
Zealand. The Australian company is currently holding 5 formulation registration dossiers in that country.
October - Ipca has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2
company has received same award for three consecutive years' 2003, 2004 and 2005
PRODUCTS:
Being one of the largest pharmaceutical corporations in India today, Ipca manufactures over 150 formulations representing various
therapeutic-segments-and-dosage-forms. The dosage forms include tablets, capsules, oral liquids, dry powders for suspension, and
injectables-(liquid&dry). Ipca also manufactures formulations for many leading companies in the European Union under supply
1) ANTI-ALLERGIC:
2) ANTI-EPILEPTIC:
Therapeutic
Generic Names Brand Name Strength Pack Size
Group
2-Bromo-6-Methoxy-Naphthalene (2BMN)
4,7-Dichloroquinoline (4,7 DCQ)
2,4-Dichloro-5-Sulphamide Benzoic Acid (Lasamide)
P-Hydroxyls Phenylacetamidem (PHPA)
6-Methoxy-2-Naphthaldehyde (6MNA)
3-Methyl Thiophene-2-Carboxaldehyde (3MeT2A)
4-(2-Methoxyethyl)phenol (MEP)
3,4,5-Trimethoxy Toluene (TMT)
2,3 Dimethoxy-5-Methyl1, 4-Benzoquione (CoQo)
2,3 Dimethoxy-5-Methyl1, 4-Hydroquine (CoQo)
2-Phenyl-2-(Pyridyl) Acetamide
2-Phenyl-2-(2-Piperidyl) Acetic Acid
4-Amino-6-Chloro-1, 3-Benzene
Located at Mumbai, Ipca’s research center is focussed on generics in regulated markets, specifically in Europe
andUSA.The center has expertise in Active Pharmaceutical Ingredients, Drug Intermediates and Formulation
1
Active Pharmaceutical Ingredients and Drug Intermediates
.
2
Formulation Development
.
Both the departments are supported by the Analytical Development cells which are fully equiped with all modern
instruments (like NMR, LC-MSMS, GCMS etc) required to carry out research on day-to-day basis. Units are geared to
continuously innovate and remain competitive by developing/acquiring abilities to find simple and effective solutions to
practical problems, solutions which are free from Patent Infringement issues.
The Active Pharmaceutical Ingredients/Drug Intermediates Research and Development department at Mumbai is
supported by two more units located at Ratlam and Indore. All the R&D units are recognized by the Department of
Science and Industrial Research, Government of India. Research & Development units at Ratlam and Indore are also
supported by facilities required for scale up of the processes from grams to kilo as well as to Pilot level.
Strengths: Innovative chemistry-driven process research leading to the generation of non-infringing routes for APIs/Drug
Intermediates and Intellectual Property. Ipca has highly qualified and experienced groups of people capable of handling
patent-related issues, which includes various aspects of patenting and patent evaluation.
This includes identification and characterization as well as structural elucidation of unknown impurities (present in APIs),
followed by their synthesis.
Analytical developments:
Process Research: Process development/improvements to make products competitive and profitable in the long run by
Non-infringing processes
2. Formulation Development :
Our Formulation Development Laboratory located at Mumbai has been gearing up for a state-of-the-art R&D facility (in
line with the US-FDA requirements). The current R&D activities are also approved by the Department of Science and
Technology, Government of India. The laboratory is well equipped with various ultramodern equipments and technologies
Ganscoata
Walk-in Stability Chambers
Press-cota
Roll compactor
Pelletisation facility
Cardiac Care
Antiinfectives
Antidiabetics
Ipca’s R & D laboratory has filed patents across the world for products based on the NDDS. Ipca’s
strength in this segment of R&D puts the company in an excellent position to compete in the growing
markets for generic drugs in Europe and USA.
Clinical Research
Aurangabad (Maharashtra)
Operational since 1997.
Manufacturing plant for Active Pharmaceutical Ingredients and Drug
Intermediates.
One of the largest manufacturers of Drug Intermediates;3,4-Trimethoxy Toulene
(TMT) and 6-Methoxy-2-Napthaldehyde (6MNA). »»
Formulations Plant
Operational since 1983.
Formulations plant manufacturing Tablets, Liquids and Injectables.
Facility approved by Brazil-Brazilian National Health
Surveillance Agency (ANVISA), South Africa-Medicines Control
Council (MCC), Geneva-World Health Organisation (WHO),
Uganda-National Drug Authority (NDA), Oman-Ministry of Health
(MOH) and Tanzania-Food & Drugs Authority (FDA). »»
THE-INDIAN-MARKET:
A country of 1.06 billion people spanning a whole subcontinent, across 3,287,590 sq. km, 29 states and 6 union territories, speaking 15 different
official languages, with myriad distinct cultures, and a heritage that goes back 5000 years, India is a country of diversity and depth like no other
in the world.
Antimalarials, Antiemetics, Antibiotics, Analgesics, Antiarthritics, Antidiabetics, Cardiac Care, Cough & Cold Therapy, Dermatology, and
Neuropsychiatry segments. Ipca manufactures over 150 formulations in virtually every dosage form: tablets, capsules, oral liquids, dry powders
for suspension, and injectables (liquid and dry). Our finished formulations are available in over 400,000 retail shops, catered to by a network of
over 1500 wholesalers. 1500 sales and marketing personnel service over 200,000 doctors across the country.
DOMESTIC APIs AND DIs: Ipca has been playing a leading role in the domestic Active Pharmaceutical Ingredients (APIs) and Drug
Intermediates (DIs) market, with over 20 years of experience in the Antimalarial and Antihypertensive therapeutic segments. We are the first
manufacturer in India for APIs like Atenolol, Pyrantel Pamoate and Hydroxychloroquine Sulfate. Our domestic pharmaceutical customers include
Alembic, Bayer, Cipla, Dr.Reddy’s, Merck, Nicholas Piramal, Pfizer, Ranbaxy, and Wockhardt, among others.
FORMULATIONS MARKETING The speciality-focussed restructuring of Ipca’s domestic marketing strategy has given birth to 8 self-
administered marketing divisions. Results are encouraging; in 2007, our domestic formulations business has grown at the rate of 16%
against an industry growth of 14% during the same period (ORG-IMS). Brands like Glycinorm, HCQS, Lariago, Malirid, Movon, Pari,
Perinorm, Ramcor, Solvin, Sultax, Tenolol, Tenoric, and Zerodol have become brand leaders in their respective therapeutic segments,
and 4 of these are also rated among the Top 300 Indian Brands (all categories) by ORG-IMS.
DOMESTIC DIVISION :
Division
The largest of Ipca’s divisions, handling the largest number of brands, this division manages our newer Antimalarials, Antihypertensives,
Antibacterials, Non Steroidal Anti-Inflammatory Drugs (NSAIDs) and Cough preparations. Recently it launched Zerodol (Aceclofenac), a country
first. Some of the other leading brands managed by this division are: Tenolol (Atenolol), Larither (Artemether), Roxeptin (Roxithromycin), and
Tenoric (Atenolol + Chlorthalidone).
Division
Ipca’s second largest division, Intima’s marketing focus is on established Anti-Infectives, and mature brands of Ipca in the Antimalarial and
Antiemetic segment. Of the several brands that Intima handles 2 are ranked among India ’s Top 250 brands (cross category). Some of Intima’s
leading brands are: Lariago (Chloroquine Phosphate), Perinorm (Metoclopramide), Pacimol (Paracetamol), Nemocid (Pyrantel Pamoate) and
Eltocin (Erythromycin Estolate).
Division
The focus of this division is on Cardiovascular and Antidiabetic segments and it currently manages 24 brands. Through the introductions of
newer dose and dosage forms, the division focuses on fulfilling the need for dose-titration, which is an essential component in the management
of diabetes and cardiovascular diseases. Some of the leading brands managed by it are: Glycinorm (Gliclazide), Glycinorm-M (Gliclazide +
Metformin), Lisoril (Lisinopril), Simlo (Simvastatin), Calchek (Amlodipine), Piomed (Pioglitazone), Metagard CR (Trimetazidine Controlled
Release) and X’tor (Atorvastatin).
Division
Bionova’s focus area is Dermatology. It has already made its mark by leading in the oral anti-acne segment with brands like Azifast
(Azithromycin) and Acutret (Isotretinoin). Also offered are fast growing brands like Leset (Levocetirizine) and Nipcan (Fluconazole).
Division
Innova marks Ipca’s entry into the Indian Neuropsychiatry segment. Already to its credit are segment leaders such as Pari (Paroxetine), Sove
(Zolpidem), and Ozapin MD (Olanzapine Mouth Dissolving). Recently, Innova launched Pari CR – India ’s first Paroxetine with Controlled Release
Technology, an international patent for which have been filed.
Division
A super-speciality division, Activa was the countries first Rheumatology and Orthopaedic – focused division. It markets a growing portfolio of
dynamic brands, including: HCQS (Hydroxychloroquine Sulfate), Folitrax (Methotrexate), Saaz (Sulfasalazine), and Movon (Aceclofenac), the
first Aceclofenac in India . Today, Activa is a leader in its segment with a 39% market share, and is also Ipca’s fastest growing division.
Division
The marketing focus of this division is on the growing need for Cardiac and Antidiabetic products. HyCare markets all major molecules for the
management of cardiovascular disease, Type II diabetes and its related complications. Glyree (Glimepiride), Glyree-M (Glimepiride + Metformin)
and Zilast (Cilostazole) are some of the leading brands of HyCare.
Division
Ipca's youngest division, Altus caters to the need of intensivists, both surgical and non-surgical, with a basket of oral and injectable
Antibiotics like Keftragard, Keftragard V, Lactagard, Lactagard 2:1, Tazofast, Primegard, Keftra, Foloup, Supraheal and Sultax
(Sulbactum + Cefotaxime), a world first.
Those seven elements are distinguished in so called hard S’s and soft S’s. The hard elements (green
circles) are feasible and easy to identify. They can be found in strategy statements, corporate plans,
organizational charts and other documentations.The four soft S’s however, are hardly feasible. They are
difficult to describe since capabilities, values and elements of corporate culture are continuously
developing and changing. They are highly determined by the people at work in the organization. Therefore
it is much more difficult to plan or to influence the characteristics of the soft elements. Although the soft
factors are below the surface, they can have a great impact of the hard Structures, Strategies and Systems
of the organization.
Description:
Effective organizations achieve a fit between these seven elements. This criterion is the origin of the other
name of the model: Diagnostic Model for Organizational Effectiveness.
If one element changes then this will affect all the others. For example, a change in HR-systems like
internal career plans and management training will have an impact on organizational culture
(management style) and thus will affect structures, processes, and finally characteristic competences of
the organization.
In change processes, many organizations focus their efforts on the hard S’s, Strategy, Structure and
Systems. They care less for the soft S’s, Skills, Staff, Style and Shared Values. Peters and Waterman in “In
Search of Excellence” commented however, that most successful companies work hard at these soft S’s.
The soft factors can make or break a successful change process, since new structures and strategies are
difficult to build upon inappropriate cultures and values. These problems often come up in the
dissatisfying results of spectacular mega-mergers. The lack of success and synergies in such mergers is
often based in a clash of completely different cultures, values, and styles, which make it difficult to
establish effective common systems and structures.
The 7-S Model is a valuable tool to initiate change processes and to give them direction. A helpful application is to
determine the current state of each element and to compare this with the ideal state. Based in this it is possible to
develop action plans to achieve the intended state.
Growth strategy:
Ipca is a market leader in the anti-malarial therapeutic category in India, enjoying 45% market share. Antimalarial
drugs accounted for 40% of its revenues around a decade ago, but now they contribute only 17%. This is due to a
diversified product mix that includes therapeutic areas like cardio-vascular, diabetes, non-steroidal anti-
inflammatory drugs and anti-bacterials . Till a few years ago, over half its portfolio comprised drugs which were
under price control, but that proportion has now fallen to 13-14%. The company also plans to foray into oncology -
another attractive therapeutic area.
In ‘05, Ipca entered into an agreement with Ranbaxy Labs for manufacturing drugs to be sold by the latter in the US.
It has signed two more such agreements with companies in the US and Canada. The branded formulations business
(spread across India, CIS, Asia, Africa and Latin America) is set to be its biggest growth driver. Ipca expects its
domestic formulations business to grow by 20% and the international segment to grow 40% this year.
System
The IPCA project aims to develop a new intelligent interaction mechanism that will enable people with severe motor
and speech disabilities to control standard, and especially web-based, applications. The system will be based on a
flexible combination of existing non-invasive sensors and encoders able to control different physiological parameters,
and a set of software tools that will allow the user to interact with existing computer applications. IPCA will facilitate
user interaction with different Internet applications and services.
• Multi-channel Monitoring System (MMS), based on non-invasive sensors able to control several physiological
parameters from the user such as: EMG, EDR, accelerometers, RR/RA, etc.
• Ambient Navigation Toolkit (ANT) that will interface between the MMS and some standard software
applications, by providing keyboard and/or mouse emulation functions. Its components are:
o Smart Web Browser that will facilitate user interaction with Internet services
o Training system
o Personal profile manager
o On-screen keyboard with scanning and word prediction capabilities
o Emotional Response Monitoring System
Structure
Ipca is always willing to try new structures in new situations. The dynamic change in the business requirements is
effectively handled by maintaining a flexible organization structure and openness. Delegation of authority and
responsibility and freedom to work has enhanced decentralization resulting in quick and effective decision making.
The senior management including Executive Directors and Managing Directors interact with employees at different
levels at different forums. Employee level or category does not restrict the access to top management. The non-
hierarchical reporting and feedback a
re being used effectively and have improved communication amongst all levels.
Power
consumption Unit 2002-2003 2003-2004 2004-2005
detail
Annual Bulk drugs &
MT 834.809 1040.281 1070.356
Production Intermediate
Form
ulatio Nos. 123481114 135824320 95455724
ns
Total Energy Bulk drugs &
consumption / Intermediate Kwh (Lacks) 105.46 131.92 153.66
annum
Form 3
ulatio 0
ns .
34.71 38.13
8
6
Total
Manufacturing Rs. Lacks 4103.23 4636.28 4442.41
cost
Total Energy Bulk drugs &
cost Intermediate Rs. lacks 555.31 746.93 903.23
Form 2
ulatio 0
ns 7
. 251.03 263.87
4
9
Form 1
ulatio 1
ns 3
792 12666
1
2
Areas of Operations
Health Environment
Safety Suppliers
Customers
Health :- We are committed to implement a programme of activities to achieve continuous improvement in health and
safety performance of our employees and society at large.
Illustration:-
- Medical checkups.
- Medical camps.
Safety:- We are committed to put our efforts to find out unsafe places and unsafe acts for improving safety of the
people at workplace and road safety for general public.
Employees:- We will deliver a competitive and fair employment environment and the opportunity to develop and
advance subject to personal performance and business opportunity.
Illustration:- - Employee education and skill development programs.
Customers:- Our business and existence depend upon our customers. Every employee is responsible for ensuring that
any contact with our customers and the public at large reflects professionalism, efficiency and honesty. We will
constantly strive to provide high quality service, products and good value for money.
Illustration:-
- Product knowledge.
- Prompt service.
Environment:- Our objective is to reduce impact on the environment through a committed continual improvement
projects for Environment Management systems.
Illustration:-
- Water conservation.
- Energy conservation.
Suppliers:- We regard suppliers as our partners and work with them to help us achieve our policy aspirations in the
delivery of our products and services.
We will encourage our suppliers and contractors to adopt responsible business policies and practices for mutual
benefit.
Illustration:-
Community at large:- We are being a responsible corporate citizen and will support for appropriate social and non-
political projects. For this purpose our organisation will focus charities in following areas.
- Employment.
- Environment.
- Rural development.
balance sheet:
2005- 2006-
Particulars 2003-04 2004-05 06 07 2007-08
Domestic
Income * 265.26 274.87 350.99 440.38 549.14
Exports 357.48 410.58 401.83 484.46 536
Total
Income * 622.74 685.45 752.82 924.84 1085.14
Earnings
before
Interest,
Depreciation
& Tax 128.51 134.48 116.62 202.52 229.16
Profit Before
Tax 108 101.55 78.39 151.24 176.87
Profit After
Tax 79.25 80.71 63.98 122.23 141.12
Share
Capital 12.5 25 25 25 25.09
Reserves
and Surplus 263.17 312.59 360.89 461.02 582.57
Net Worth 275.67 337.59 385.89 486.02 607.7
Net Block 195.92 322.46 373.52 431.48 541.04
Net Current
Assets 248.27 268.52 243.23 319.79 445.12
Dividend
(%) 110% 55% 55% 75% 80%
Earnings
Per Share
(Rs.) 63.41 32.28 25.59 48.89 56.38
Book Value
Per 220.5 ** 135.0 242.2
Share(Rs.) 4 4 154.36 194.41 1
Domestic
Turnover/Total Income 46.62 45.92 46.12 38.76 39.35
Raw Material
Cost/Total Income 42.67 43.02 46 42.29 43.6
Research
Spending/Total Income 4.12 3.61 5.05 4.97 4.12
Profitability (in Percent)
Return on Capital
Employed %
(ROCE = PBIT/(Net
Worth + Long Term
Liability) 23.26 26.18 17.03 22.31 32.46
Creditors Turnover
Ratio (Days) 69 72 78 69 66
Inventory Turnover
(Days) 91 93 89 94 91
Current Ratio 1.83 1.79 1.73 1.9 1.68
Growth (in percent)
Income 17.3 22.9 9.8 10.1 28.58
Sales/Income from Operations 867.24 261.52 231.98 1128.76 978.09 1137.86 997.22
Less: Excise Duty and Sales Tax 38.73 7.70 9.07 46.43 56.98 46.43 56.98
Net Sales/Income from Operations 828.51 253.82 222.91 1082.33 921.11 1091.43 940.24
Total Expenditure:
c) Purchase of traded goods 37.64 5.98 10.68 43.62 50.46 49.44 54.47
f) Manufacturing and other expenditure 175.59 73.41 52.55 249.00 210.61 255.15 218.00
Profit from ordinary activities before tax 152.13 24.74 28.50 176.87 150.40 175.26 154.31
Profit from ordinary activities after tax 118.48 22.64 27.65 141.12 121.39 135.93 125.33
Extraordinary items
Net Profit for the period 118.48 22.64 27.65 141.12 122.23 135.93 126.17
Notes:
1. The above audited financial results as reviewed by the Audit Committee were approved and taken on record by the Board of Directors
in their meeting held on May 29, 2008.
2. The Board has recommended a Final Dividend of Rs.4.50 per share (45%) for the financial year 2007-08. Together with the Interim
Dividend of Rs.3.50 per share (35%) already declared and paid, the total Dividend for the financial year amounts to Rs.8 per share
(80%).
3. The Company has completed the process of open offer in April 2008 to the shareholders of M/s Tonira Pharma Ltd. under Regulation
10 and 12 of SEBI (SAST) Regulations and has since gained the management control of the said company as the largest shareholder
holding 32.30% of its voting rights.
4. Previous year figures have been regrouped, wherever necessary.
5. The entire operations of the Company relate to only one segment viz.'Pharmaceuticals'.
6. 24 investor grievances were received for the quarter ended 31st March, 2008 and disposed off. There are no investor grievances lying
unresolved as at 31st March, 2008.
By Order of the Board
For Ipca Laboratories Limited
The end.
Section: Imagination
Content
Company profile:
Products:
Ipca’sR&D:
Financial Report(2003-2008):